IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 3, January 2024

Analyzing Immune Responses to Biopharmaceuticals

Basawaraj Kadangi[1] and Dr. Ashish M kandalkar[2]
Research Scholar, Department of Pharmacy[1]
Research Guide, Department of Pharmacy[2]
Sunrise University, Alwar, Rajasthan, India

Abstract: *Biopharmaceuticals may increase an immunogenic response in patients receiving treatment, which might have an effect on the medication's safety and effectiveness. Therefore, it is crucial to assess immunogenicity at every stage of a biopharmaceutical's clinical development, including post-marketing surveillance. Regulatory agencies mandate a thorough assessment of biopharmaceutical immunogenicity, but there are no consistent guidelines regarding the kind, amount, and caliber of evidence, nor are there guidelines for designing immunogenicity assays or comparing the immunogenicity of biopharmaceuticals. Additionally, significant technical advancements in immune response assessment methodologies have led to greater immunogenicity rates using contemporary assays, which restricts the comparison of biopharmaceuticals' immunogenicity outside of head-to-head clinical trials. Because of this, research initiatives, regulatory bodies, and medical professionals must stay up to date with the always changing assessments of immunogenicity. Here, we go over the variables that affect how immunogenic biopharmaceuticals are, possible clinical consequences, the latest regulatory guidelines for assessing immunogenicity, and how to measure immunogenicity in both non-clinical and clinical research. Additionally, we outline unique factors to take into account when assessing the immunogenicity of potential biosimilars*

Keywords: Antibody Formation, Immune Response, Risk Assessment, Clinical Trials.

I. INTRODUCTION

Biopharmaceuticals are medicines created by living things; they are often created by genetically modifying live bacteria, plants, or animals. Biopharmaceuticals have improved patient care by offering extremely effective, targeted treatments for a variety of chronic and life-threatening illnesses, including solid tumors and hematologic malignancies, as well as systemic immune-mediated illnesses like psoriasis, inflammatory bowel disease, rheumatoid arthritis, and systemic lupus erythematosus. Biopharmaceuticals, in contrast to small-molecule medications, are usually huge and very complicated, requiring lengthy manufacturing schedules and highly specialized processes to make.

Versions of the original biopharmaceutical molecule that have shown structural, functional, efficacious, and safety similarities to the reference product are known as biosimilars. The creation of biosimilars may improve patient and physician access to treatment and therapy choices, resulting in cost savings and increased efficiency for both local and national healthcare systems.

The regulatory approval procedure for biosimilar prospects differs from that for generic copies of small-molecule medications because of the inherent differences in manufacturing techniques and the underlying complexity of biopharmaceuticals. Guidelines for determining biosimilarity have been released by the World Health Organization, European Medicines Agency, and US Food and Drug Administration. Similar to the FDA, EMA, and WHO recommendations, other nations have also created their own guidelines for the production of biosimilars. Despite occasional differences in the kind and volume of supporting material, regulatory authorities base their approval on the whole body of evidence. A number of national academic bodies, colleges, and societies have also released policy statements about the clinical usage and approval procedures for biosimilars. These recommendations support strict guidelines for the approval of biosimilars, post-marketing pharmacovigilance, and the extrapolation of safety and effectiveness information for indications not covered by clinical studies.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 3, January 2024

Biopharmaceuticals, particularly biosimilars, may cause an immunogenic response in patients receiving treatment, which might affect the medication's safety and effectiveness characteristics. Immunogenicity must thus be assessed at every stage of clinical development as well as during post-marketing monitoring. Over the last 20 years, prevailing theories and techniques for determining immunogenicity have changed. In this article, we examine immunogenicity-related variables, potential clinical implications, and the most recent regulatory guidelines for assessing immunogenicity. We also go over how to evaluate in both non-clinical and clinical trials the immunogenicity of biopharmaceuticals, including biosimilars. Furthermore, we examine the protocols for overseeing immunogenicity after regulatory clearance within the framework of evolving guidelines and methods for assessing immune reactions.

Considerations for Assessing Immunogenicityof Biopharmaceuticals

Anti-Drug Antibodies and ClinicalAdverse Effects

The presence of anti-drug antibodies seen in the bloodstream of either people or animals after the administration of a biologic is what defines immunogenicity. Neutralizing antibodies (ADAs) are defined as those that attach to a biopharmaceutical's active site and may impede its function. Even while non-neutralizing antibodies do not bind to the active site, they may nonetheless have significant clinical effects, such as lowering the effectiveness of treatment by reducing bioavailability. More and more research is pointing to the production of ADAs as a possible cause of certain biopharmaceuticals' decreased effectiveness or therapeutic failure. This might happen due to changed medication pharmacokinetics or, in other cases, neutralizing antibodies attached to active sites that decrease drug action.

ADAs have been linked to a variety of safety hazards, from minor to fatal incidents. Adverse drug reactions (ADAs) after therapeutic delivery may not always result in clinically significant effects on safety or effectiveness. In actuality, immunogenicity-related side effects including hypersensitivity are quite rare. Additionally, deficient syndromes might result from neutralizing antibodies reacting with endogenous proteins. Thus, unintended immunogenicity may provide a significant challenge to the creation of biopharmaceuticals.

Key Elements Influencing Immunogenicity

Numerous variables may affect immunogenicity, which can be divided into three main categories: factors related to pharmacological properties, patients, and therapy. The route of administration, length of therapy, and frequency of administration, for instance, are treatment-associated characteristics that might all impact the chance of an immunological response. Patient-associated variables include illness condition, polymorphisms in major histocompatibility complex that might impact the strength of T cell-dependent immune responses, and immune system function, which when weakened may reduce the likelihood of building antibodies. Glycosylation and the degree of humanization of a biopharmaceutical are two parameters related to drug properties patterns, and removal or concealment of MHC epitopes by design, as well as issues that arise during the manufacturing process, such as the presence of impurities, aggregates, and contaminants

Immunogenicity Assessments

Overall Approach

A systematic method is used in clinical research to assess the immunogenicity of biopharmaceuticals. To find out whether treated patients have ADAs, a screening test is used first. Confirmatory tests are next conducted to ascertain the ADAs' specificity for the biopharmaceutical and to get rid of erroneous positives. Bioassays or ligand-binding assays are utilized to discover neutralizing antibodies, and characterisation tests are performed to assess the titer and type of ADAs for ADA-positive samples. Immunogenicity evaluations are carried out in combination with pharmacokinetic, safety, and effectiveness studies, with the whole of the data taken into consideration, in order to determine the possible clinical impact of ADAs.

ADA Screening Assays

Biopharmaceuticals have been screened for ADAs using a range of methods, and during the last 20 years, methodology has significantly improved. Electrochemiluminescence assays, radioimmunoassays, and enzyme-linked immunosorbent assays, which may be performed in an indirect, direct, or capture manner, are examples of frequently used assays. It is

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 3, January 2024

possible to alter some of these tests to make them "drug tolerant." As every format has its own set of advantages and disadvantages, no one test is suitable for determining the immunogenicity of all biopharmaceuticals. A crucial factor in the development of biopharmaceuticals is choosing the best assay for ADA screening, which requires careful evaluation of the characteristics of the treatment under examination.



Fig. 1 Stepwise approach to assessing immunogenicity of biopharmaceuticals. ADA anti-drug antibody

Assay Types

The high-throughput capabilities, simplicity of use, and convenience of ELISAs make them a popular choice for immunogenicity screening. In a direct ELISA, biopharmaceuticals are immobilized on plastic plates to extract anti-drug antibodies (ADAs) from patient samples.



Fig. 2 Evolution of immunogenicity assays for biopharmaceuticals and assessment of anti-adalimumab antibodies

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 3, January 2024

After many washings of the plate, the ADAs are detected spectrophotometrically using a colorimetric tagged anti-immunoglobulin reagent. For therapeutic monoclonal antibodies, direct ELISAs are not suitable due to the possibility of cross-reactivity. The biopharmaceutical's attachment to a plastic surface may change its conformation and hide epitopes, which might lead to an underestimate of ADAs. This is one of the limitations of the direct ELISA. This issue is avoided by the indi-rect ELISA format, which first immobilizes antibodies on the plate to position the biopharmaceutical. The direct and indirect ELISA formats have drawbacks such as false positives and excessive

The following immunoassays may contain background noise from non-specific binding: ADA anti-drug antibody, ADL adalimumab, ARIA acid-dissociation radioimmunoassay, ECL electrochemiluminescence, ELISA enzyme-linked immunosorbent assay, PIA pH-shift anti-idiotype antigen-binding test, and TRIA temperature-shift radioimmunoassay. A conjugated version of the biopharmaceutical is used to detect ADAs in a capture ELISA, where they are first caught by an immobilized biopharmaceutical. Although this version is more focused and specialized than either the direct or indirect forms, there is still a chance to lose low-affinity ADAs.

The ECL assay works on the same principles as an ELISA, but it is more suited for assessing monoclonal antibody pharmaceuticals since it uses a ruthenium-conjugated protein for detection instead of an antibody. The assay's sensitivity is enhanced by the ruthenium-conjugated protein complexes' dynamic range when compared to ELISA. Radioimmunoassay is one kind of antigen-binding test where ADAs from patient sera are bound to protein A on sepharose and then detected with 125I-adali- mumab. Although this method is more sensitive than ELISA, researchers may be discouraged from using it because of the radioactivity involved. In surface plasmon resonance tests, bound ADAs from patient samples generate a signal as a result of a change in mass using a sensor with immobilized biopharmaceuticals. While the capacity to detect low-affinity ADAs and distinguish between antibody isotypes and continuous measurements of ADAs are benefits of this technology, it may not be as sensitive as the other assays outlined and cannot be utilized for high-throughput analysis.

Medication interference may make it difficult to identify ADAs in the tests. ADAs may exist, however they are often attached to excess biopharmaceuticals, making it difficult for ADA tests to identify the ADA in this ADA–biopharmaceutical complex and producing false-negative findings. Long half-lives of biopharmaceuticals may make this a special issue. Novel drug-tolerant assays have been designed to detect both bound and free ADAs, as shown by the development of anti-adalimumab antibodies, in order to get around this possible restriction. These include pH-shift anti-idiotype antigen-binding tests and other acid-dissociation radioimmunoassays. temperature-shift radioimmunoassays, homogeneous mobility-shift assays, and affinity capture elution assays Before ADA is detected, these assays separate ADA–biopharmaceutical complexes using various methods. For example, in the PIA, samples are neutralized prior to ADA screening after bound ADAs are freed by acid treatment. When directly compared to more conventional tests like ELISA or radioimmunoassay, these more recent techniques have produced greater rates of immunogenicity, as would be predicted owing to their enhanced sensitivity.

Whichever approach is used to screen for ADAs, accurate method validation is necessary to guarantee repeatable, reliable, and conclusive findings. This stage should be completed as soon as possible in the clinical development of a biopharmaceutical. Throughout the pre-approval process, it could be necessary to monitor and modify the product on an ongoing basis. Validation criteria for immunoassays should include cut-points, sensitivity, drug tolerance, specificity, accuracy, dilution, and reproducibility, as they are detailed in previously published recommendations. The experimental approaches for assessing immunogenicity cannot be calibrated due to disagreements about reference standard use, hence the tests are only quasi-quantitative. As a result, both positive and negative controls are required in tests.

Analysis of ADA Samples

Cut-points are used to establish boundaries and categorize samples as either positive or negative for the ADA. Prior to conducting immunogenicity assessments on patient samples, cut-points must be pre-defined and are determined by looking at the signals seen in negative controls. The choice of positive control will dictate the assay's sensitivity; greater-affinity positive controls will result in higher sensitivity. For clinical studies, sensitivity ranges of 250–500 ng/mL have been suggested. It is also essential to determine the drug tolerance limit because of the possible problem of drug interference, which is discussed in Sect. The selection of positive control has an effect on the drug-tolerance threshold, similar to the sensitivity parameter; higher-affinity positive controls result in lower tolerance.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 3, January 2024

After the first round of ADA screening, a confirmatory test is conducted using the same screening techniques with the addition of drug competition/immunodepletion. To saturate ADA-binding sites, samples are first treated with an excess of the biotherapeutic test protein. In the event that the antibodies found during screening are in fact specific to the pharmaceutical, this pre-incubation stage will reduce or eliminate a positive signal in the confirmation test that comes after. To remove false positives, a confirmatory cut-point is required. It is determined empirically, ideally in conjunction with the calculation of the screening cut-point. The confirmatory test may be carried out in combination with ADA, titer, and immunoglobulin subtype characterization.

Neutralizing Antibody Assays

Cell-based bioassays or competitive ligand-binding assays should be used to check for neutralizing antibodies in samples that have been confirmed to be ADA positive. While the read-out for competitive ligand-binding assays is inhibition of target binding, the data output for cell-based assays is suppression of biopharmaceutical activity. The FDA recommends cell-based bioassays to monitor the biopharmaceutical's function in the presence of neutralizing antibodies because they better reflect the conditions in treated patients and may provide insight into the possible clinical implications of immune responses to biopharmaceuticals. However, it might be time-consuming and challenging to design and evaluate cell-based methods.

The best test to assess biologic activity inhibition will depend on the biopharmaceutical's mode of action. Similar to ADA screening tests, validation factors such as medication tolerance, cut-points, and specificity should be included, along with positive and negative controls.

Immunogenicity Assessments: A PracticalApproach

Patients in clinical trials should be assessed at baseline for immunogenicity; if a patient has previously had therapy with a biopharmaceutical and has pre-existing ADAs, stratified randomization based on treatment history may be taken into consideration. Furthermore, in immunogenicity investigations, it is essential to assess the kinetics of ADA formation at many sampling times in order to distinguish between pre-existing and drug-induced immunological responses, as well as between transitory and permanent immune responses.

It is a difficult task to design an immunogenicity risk assessment strategy that satisfies all standards for biopharmaceutical approval. However, a risk-based strategy has been suggested to create immunogenicity evaluations in clinical trials, taking into account the targeted patient group, biopharmaceutical features, and known safety concerns with similar products.

Variability in Immunogenicity Assays: A CaseStudy in Adalimumab

Even when a single biopharmaceutical is examined in a specific patient group, heterogeneity in the design and execution of tests may emerge as significant variances in immunogenicity rates, in addition to the many biopharmaceuticals and patient characteristics that may impact immunogenicity. The greater sensitivity and robustness of newer methodologies are responsible for higher ADA detection rates with contemporary tests when compared to data from previous research. This should not be taken as increasing immunogenicity of biopharmaceuticals over time.

Studies on the immunogenicity of adalimumab, an antibody to tumor necrosis factor-a that is licensed for the treatment of a number of inflammatory diseases, provide an example of the aforementioned occurrence. Analyses was out on RA patients between 2003 and 2015 revealed ADA rates ranging from 1 to 66%. In investigations using conventional tests, ADA rates less than 10% were observed in this patient group alone by ELISA. It should be mentioned that individuals taking concurrent methotrexate, which has been shown to prevent ADA development, had ADA rates of less than 1%. Conversely, utilizing antigen-binding tests, including radioimmunoassays, greater rates of immunogenicity (13–29%) were seen in methotrexate-using individuals. Bridging ELISA found less ADA-positive samples than radioimmunoassay in a cohort of 216 patients with RA treated with adalimumab, and the ELISA is more susceptible to medication interference, according to a direct comparison of these two techniques. As expected, when directly compared to conventional antigen-binding tests, drug-tolerant assays that were intended to identify both free and bound antibodies had greater ADA rates.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 3, January 2024

The wide variety of immunogenicity rates seen in RA patients treated with adalimumab, based on various assay types and across trials using the same technique, highlights the limitations of inter-trial comparisons of biopharmaceutical immunogenicity. Developing Guidelines and Procedures for Evaluating Biopharmaceuticals' Immunogenicity

Regulatory Guidelines

Evaluating the immunogenicity of biopharmaceuticals is mandatory for regulatory approval Specific guidance for evaluating immunogenicity of therapeutic

The FDA and EMA have supplied protein products. Additionally, the EMA has created precise standards for evaluating immunological reactions to therapeutic monoclonal antibodies.

The creation of assays that can reliably identify and confirm the presence of ADAs, as well as methods for differentiating between neutralizing and non-neutralizing antibodies, systematic patient data collection in clinical studies, and standardization of procedures for a particular biopharmaceutical are among the recommendations. The FDA and EMA also caution that although information gathered from preclinical toxicological research may be enhanced, data from immunogenicity evaluations in animals may not always be predictive of immune responses in people. Additionally, both agencies seem to be in favor of using a single test to assess immunogenicity.

Post-Approval Surveillance of Immunogenicity

Immunogenicity assessments in biopharmaceutical clinical trials may not represent real-world clinical experience due to tight qualifying criteria and short-term follow-up. Indeed, all biopharmaceuticals must undergo safety (including immunogenicity) testing after licensure. Long-term follow-up of RA patients treated with adalimumab or infliximab indicated that ADAs reduce clinical response and cause premature therapy termination. Clinical studies seldom discover immune responses that cause life-threatening, rare safety concerns. Post-approval, cross-reactive anti-erythropoietin antibodies caused a significant rise in pure red-cell aplasia in patients on recombinant erythropoietin, which coincided with a manufacturing process and formulation change. Thus, post-approval immunogenicity surveillance is crucial, and observational clinical and laboratory test datasets from biopharmaceutical patients in ordinary clinical practice may give further information. The FDA, EMA, and WHO propose including immunogenicity in pharmacovigilance and risk management plans for all biopharmaceuticals, including biosimilars, although only the EMA specifies post-approval monitoring procedures.

Risk-based immunogenicity evaluation for biopharmaceuticals has been proposed for post-approval safety monitoring programs as well as clinical trials. To prepare pharmacovigilance strategies, inadequate ADA detection in clinical trials may underestimate risk. Based on the biopharmaceutical's properties and pre-approval clinical trial immunogenicity rates, the risk management plan for unwanted immunogenicity may include additional clinical studies, retrospective analyses of real-world use, pharmacovigilance, and prescribing information provisions. Biopharmaceuticals that induce lasting immune responses may cause ADA cross-reactivity in patients who transition to biosimilars or novel biopharmaceuticals. The risk management strategy should account for this.

Post-approval registries may assess long-term immunogenicity by monitoring ADA levels in patients treated with biopharmaceuticals with a high immunogenicity risk. Tracking anti-TNF-a bio-pharmaceuticals and ADAs in chronic inflammatory disease patients may help clinicians adjust dosage or switch therapies. However, a recent research suggests that adalimumab and etanercept blood ADA levels do not predict RA dosage decrease or discontinuation.

Additional Considerations for BiosimilarImmunogenicity Assessments

FDA, EMA, and WHO require clinical trials of biosimilars to compare immunogenicity to reference products. The biosimilar safety assessment requires immunogenicity similarity to the reference product since even slight product quality changes (impurities and contaminants) might affect immunogenicity. While the EMA and WHO do not need biosimilar immunogenicity testing in preclinical animal trials, FDA guidance says that these analyses may give important data but are not required. However, animal studies of biosimilar immunogenicity may help regulatory authorities establish cross-reactive and neutralizing antibody titers.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 3, January 2024

Due to more sensitive and specific tests, historical immunogenicity data for the reference product should not be utilized to compare the biosimilar to it. However, it may help clinical developers analyze biosimilar immunogenicity. Biosimilars and reference products should be compared.

Comparative immunogenicity may be done using one or two assays. The one-assay method detects biosimilar and reference product ADAs using the biosimilar reagent. This strategy optimizes biosimilar ADA detection and comparison, but it may lose immunogenicity information on the reference product. In the two-assay method, each test measures biosimilar or reference product ADA. This approach can analyze biosimilar and reference product ADAs but takes time and money. Each technique has pros and downsides, and choosing one to compare immunogenicity is crucial for biosimilar clinical trials. In order to reduce bias, biosimilar immunogenicity assessments should employ a proven one-assay technique to verify comparable ADA rates with the reference product rather than generate new information about it.

The inability to categorize a clinically relevant difference in ADA rate as different immunogenicity is a biosimilar development challenge. Due to bioanalytical biases and a lack of understanding of how ADAs affect short-term and long-term effectiveness and safety, ADA rates alone may not completely explain biosimilar and reference biopharmaceutical immunogenicity profiles. Thus, pre-defining a biosimilarity-supporting immunogenicity rate differential between biosimilars and reference products is impractical. According to regulatory standards, biosimilar ADA rates should be addressed in the context of drug trough concentrations and effectiveness and safety outcomes when assessing biosimilar approval. It is evident that greater biosimilar immunogenicity rates than the reference product would raise doubt on biosimilarity, whereas lower immunogenicity has unclear consequences. The reduced immunogenicity of a biosimilar does not preclude its approval, but it does not mean it improves efficacy or safety. Regulators may recommend subgroup analyses in patients with and without immune responses to help interpret clinical trial efficacy results.

A biosimilar risk management strategy should include any safety issues related to manufacturing process variations from the reference biopharmaceutical, according to the EMA. Because pharmacological property-associated characteristics like glycosylation patterns or aggregation formation might impact immunogenicity, post-approval biosimilar formulation or manufacturing modifications may necessitate further research.

Immunogenicity, including assay revalidation Extrapolation of biosimilar indications or plans for pediatric usage may need further immunogenicity evaluations, depending on patient-specific characteristics in the new population to be treated.

Biosimilars should be distinguished from non-similar biopharmaceuticals (also called ‘intended copies’ or biomimics), which may not have been thoroughly tested for physicochemical and functional properties, efficacy, safety, and immunogenicity against a reference product. Pre-existing regulation in various Latin American and Asian nations allows biopharmaceutical replicas to be licensed without fulfilling the rigorous biosimilarity criteria outside of these regions. These products are intended replicas, not biosimilars, since they may not have equivalent effectiveness and safety. A Mexican regulatory agency recalled a planned copy of rituximab owing to a lack of biosimilarity data and complaints of anaphylactic reactions in patients who switched between the reference product and the intended copy. This was seen despite indications that Mexicans had little peri-infusion responses to the originator's rituximab. These results emphasize the need for thorough biosimilar safety testing, including immunogenicity, before widespread usage. Biosimilarity is determined by rigorous, high-quality product attribute comparison, including immunogenicity factors.

Lessons Learned and Recommendations

All biopharmaceuticals, including biosimilars, must undergo immunogenicity testing. Technology has advanced over the last two decades, but uneven research methodology limits biopharmaceutical immunogenicity comparisons outside of head-to-head clinical trials. Strong regulatory guidelines on immunogenicity evaluation would help address approach heterogeneity. In the meantime, the American Association of Pharmaceutical Scientists and the Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk consortium have advocated aligning biopharmaceutical immunogenicity research and understanding. To study immune responses to biopharmaceuticals, these two organizations advocate standardizing language and data reporting and tying ADAs to effectiveness, safety, and pharmacokinetic outcomes. These proposals may help standardize immunogenicity evaluation.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 3, January 2024

Since biopharmaceuticals were introduced, we know more about immunogenicity and how to detect undesired immune responses. Immunogenicity test accuracy and sensitivity have improved and will likely continue to improve. Modern tests show increased immunogenicity. Physicians should be aware of these upgraded technologies and not assume new biopharmaceuticals, including biosimilars, are immunogenic. With biosimilars and clinical trial comparisons, state-of-the-art technologies may provide new immunogenicity data on licensed biopharmaceuticals. As innovative methods like genetic and epigenetic biomarker evaluation and in silico immunogenicity prediction develop, immunogenicity studies will change, improving patient risk assessment. Thus, research programs, regulatory agencies, and doctors must keep up with more complicated immunogenicity analyses.

REFERENCES

[1]. Morrow T, Felcone LH. Defining the difference: what makes bologics unique. Biotechnol Healthc. 2004;1(4):24–9.

[2]. Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol. 2010;28(9):917–24.

[3]. Wang J, Chow SC. On the regulatory approval pathway of biosimilar products. Pharmaceuticals (Basel). 2012;5(4):353–68. doi:10.3390/ph5040353.

[4]. Bennett CL, Chen B, Hermanson T, Wyatt MD, Schulz RM, Georgantopoulos P, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014;15(13):e594–605. doi:10.1016/S1470-2045(14)70365-1.

[5]. US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. SIlver Spring: U.S. Department of Health and Human Ser- vices, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2015 (last update Apr 2015). http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM291128.pdf. Accessed 23 Mar 2015.

[6]. European Medicines Agency, Committee for Medicinal Products forHuman Use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active sub- stance: non-clinical and clinical issues. London: EMA; 2013 (last update 3 June 2013). http://www.ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/2013/06/WC500144124.pdf.Accessed 23 Mar 2015.

[7]. World Health Organization, Expert Committee on Biological Standardization. Geneva, 19 to 23 October 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva: WHO; 2009 (last update 19–23 Oct 2009). http://www.who.int/ biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_ FOR_WEB_22APRIL2010.pdf. Accessed 21 Apr 2015.

[8]. Espinosa Morales R, Diaz Borjon A, Barile Fabris LA, Esquivel Valerio JA, Medrano Ramirez G, Arce Salinas CA, et al. Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012. Reumatol Clin. 2013;9(2):113–6. doi:10. 1016/j.reuma.2012.11.001.

[9]. American College of Rheumatology. American College of Rheumatology position statement: biosimilars. Atlanta: ACR; 2015. http://www.rheumatology.org/Portals/0/Files/Biosimilars.pdf. Accessed 27 May 2015.

[10]. Barosi G, Bosi A, Abbracchio MP, Danesi R, Genazzani A, Corradini P, et al. Key concepts and critical issues on epoetin andfilgrastim biosimilars. A position paper from the Italian Societyof Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica. 2011;96(7):937–42. doi:10.3324/haematol.2011.041210.

[11]. Fiorino G, Girolomoni G, Lapadula G, Orlando A, Danese S, Olivieri I. The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev. 2014;13(7):751–5. doi:10.1016/j.autrev.2014.02.004.

[12]. Arguelles-Arias F, Barreiro-de-Acosta M, Carballo F, Hinojosa J, Tejerina T. Joint position statement by ''Sociedad Espanola de Patologia Digestiva'' (Spanish Society of Gastroenterology) and ''Sociedad Espanola de Farmacologia'' (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory boweldisease. Rev Esp Enferm Dig. 2013;105(1):37–43.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 3, January 2024

[13]. Fonseca JE, Goncalves J, Araujo F, Cordeiro I, Teixeira F, Canhao H, et al. The Portuguese Society of Rheumatology position paper on the use of biosimilars. Acta Reumatol Port. 2014;39(1):60–71.

[14]. Mularczyk A, Gonciarz M, Bartnik W, Durlik M, Eder P, Gasior-owska A, et al. Biosimilar medicines—their use in the treatment ofinflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. PrzGastroenterol. 2014;9(1):1–3. doi:10.5114/pg.2014.40842.